1859 is industrializing the pursuit of new small molecule therapies through a unique combination of miniaturized assays, high-throughput screening, and AI.
Aro combines advances in protein engineering, nucleic acid chemistry, and disease gene biology to achieve cell-specific oligonucleotide delivery.
CAMP4 is a preclinical biotech company pioneering the field of upregulation to restore healthy gene expression in diseased cells by programmable modulation of a new class of RNA called regRNA.
Candel is a late stage clinical biotechnology company developing oncolytic viral immunotherapies for the treatment of high unmet need cancers such as prostate and glioblastoma.
Code Bio is pioneering the development of targeted, non-viral medicines to treat and potentially cure serious and life-threatening diseases.
Curie.Bio helps founders launch successful therapeutics companies by serving as their drug discovery copilot and seed investor.
DICE enables the convenience of an oral medicine with the efficacy of existing biologics to create new medicines for patients suffering from debilitating autoimmune diseases.
Garuda Therapeutics is creating off-the-shelf blood stem cell therapies to provide accessible, tailored alternatives for all patients in need.
Incendia Therapeutics is reimagining the tumor microenvironment by creating anti-cancer therapies that lead to more effective treatment.
Kyverna is a clinical-stage cell therapy company advancing a new class of curative therapies for inflammatory and autoimmune diseases.
Mestag Therapeutics is targeting activated fibroblast populations to influence the immune system and create impactful new medicines.
OMass Therapeutics harnesses native mass spectrometry alongside proprietary biochemistry and custom chemistry to discover therapeutics for immunological and rare diseases.
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics targeting multiple drivers of cancer.
StrideBio is a developer of engineered adeno-associated virus (AAV) based gene therapies with life-changing or curative potential for children and adults.
Totus scalably invents covalent medicines with the potential for superior safety and efficacy.
Transition Bio is a microfluidics- and machine learning-driven company working to harness the potential of biomolecular condensates in revolutionizing drug discovery.
Triumvira is a clinical stage oncology cell therapy company developing a pipeline of novel autologous and allogeneic therapies with enhanced safety and efficacy over current approaches.
Vigil Neuroscience is the world’s first microglia-focused biotechnology company focused on treating rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system.
Walking Fish engineers B cells to stimulate the immune system and produce protein therapeutics for oncology, rare deficiency diseases, autoimmune diseases, and more.